Equities researchers at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the medical technology company’s stock.
Several other analysts also recently weighed in on BIOL. Maxim Group downgraded BIOLASE from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 24th. Benchmark reiterated a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a report on Monday, August 12th.
Get Our Latest Research Report on BIOLASE
BIOLASE Price Performance
BIOLASE (NASDAQ:BIOL – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical technology company reported ($0.08) earnings per share for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 43.56%. The business had revenue of $11.56 million during the quarter.
Institutional Inflows and Outflows
An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC grew its holdings in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned approximately 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.79% of the company’s stock.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Further Reading
- Five stocks we like better than BIOLASE
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Retail Stocks Investing, Explained
- Why Dell Can Continue Winning in AI and Beyond
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.